Big Pharma makes an even bigger footprint in Maryland: AstraZeneca, a heavyweight in life sciences, is expanding its Gaithersburg presence with a $2 billion facility, set to amp up job numbers and cling onto an existing employee base. Maryland Governor Wes Moore and Montgomery County Executive Marc Elrich raised glasses on Friday to toast this investment, which is set to churn out clinical trial molecules, according to Montgomery County's official announcement.
The facility is not just another building. It’s a major play to keep Maryland a key player in the biotech game. "This landmark investment strengthens the U.S. medicine supply chain and accelerates the development of life-saving therapies," Gov. Moore told attendees, touting Maryland as a leading life sciences state. County Executive Marc Elrich not only patted the state's back but also zeroed in on talent, community, and the innovation ecosystem as magnets for AstraZeneca's decision.
Here's what the Gaithersburg expansion means in digits: 100 new jobs on board, 400 roles retained, and an estimated 1,000 construction jobs in play. The gears are expected to turn at full steam by 2029, with the city of Gaithersburg giving its blessing to expedite the setup. Rep. April McClain Delaney threw in her two cents, saying, "This historic investment is fantastic news for our communities, businesses, and workers along the I-270 Technology Corridor," in a statement noted by Montgomery County's press release.
AstraZeneca's CEO Pascal Soriot added to the choir, underscoring the company's allegiance to Maryland's economy and noting the rare disease portfolio coming to the American shores for the first spell. As the state's largest biopharmaceutical employer, the company reflects the synergy between a global outlook and Montgomery County's international identity and diverse talent pool.
On the economic front, County Council President Kate Stewart highlighted the boon this investment will be to advances in medical treatments. The Montgomery County Economic Development Corporation's board chair, Elana Fine, expressed exhilaration over this move and the strength of the County's life sciences ecosystem. This new Gaithersburg facility, following on the heels of a recent $300 million cell therapy facility in Rockville, is poised to make use of state-of-the-art AI and automation to boost advanced manufacturing and set the pace in technology within the County.
